QURE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
QURE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-13), uniQure NV's share price is $4.92. uniQure NV's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.07. Hence, uniQure NV's Price-to-Operating-Cash-Flow Ratio for today is .
The historical rank and industry rank for uniQure NV's Price-to-Operating-Cash-Flow or its related term are showing as below:
During the past 13 years, uniQure NV's highest Price-to-Operating-Cash-Flow Ratio was 51.21. The lowest was 2.13. And the median was 4.90.
uniQure NV's Cash Flow from Operations per share for the three months ended in Dec. 2023 was $-1.04. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.07.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -0.30% per year.
During the past 13 years, uniQure NV's highest 3-Year average Operating Cash Flow per Share Growth Rate was 5.10% per year. The lowest was -107.00% per year. And the median was -8.00% per year.
The historical data trend for uniQure NV's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
uniQure NV Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Price-to-Operating-Cash-Flow | Get a 7-Day Free Trial | - | - | 3.37 | - | - |
uniQure NV Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Price-to-Operating-Cash-Flow | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, uniQure NV's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, uniQure NV's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where uniQure NV's Price-to-Operating-Cash-Flow falls into.
uniQure NV's Price-to-Operating-Cash-Flow ratio for today is calculated as
Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
= | 4.92 | / | -3.068 | |
= |
uniQure NV's Share Price of today is $4.92.
uniQure NV's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.07.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Price-to-Operating-Cash-Flow Ratio | = | Market Cap | / | Cash Flow from Operations |
Thank you for viewing the detailed overview of uniQure NV's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Walid Abi-saab | officer: Chief Medical Officer | C/O UNIQURE N.V., PAASHEUVELWEG 25A, AMSTERDAM P7 11058BP |
Ricardo Dolmetsch | officer: President, R&D | 113 HARTWELL AVENUE, LEXINGTON MA 02421 |
Pierre Caloz | officer: Chief Operating Officer | UNIQURE N.V., PAASHEUVELWEG 25A, AMSTERDAM P7 P7 11058BP |
Madhavan Balachandran | director | C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873 |
Rachelle Suzanne Jacques | director | C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062 |
Robert Gut | director | C/O VERSARTIS, INC., 4200 BOHANNON DRIVE, SUITE 250, MENLO PARK CA 94025 |
Leonard E Post | director | |
Christian Klemt | officer: Chief Financial Officer | PAASHEUVELWEG 25A, AMSTERDAM P7 1105 BP |
Jack Kaye | director | C/O KERYX BIOPHARMACEUTICALS, 750 LEXINGTON AVENUE, NEW YORK X1 10022 |
Jeremy P. Springhorn | director | C/O UNIQUIRE N.V., 113 HARTWELL AVENUE, LEXINGTON MA 02421 |
David D. Meek | director | 3000 KENT AVENUE; SUITE A1-100, WEST LAFAYETTE IN 47906 |
Paula Soteropoulos | director | 49 WINONA STREET, PEABODY MA 01960 |
Jeannette Potts | officer: See Remarks | C/O FORMA THERAPEUTICS HOLDINGS, INC., 500 ARSENAL STREET, SUITE 100, WATERTOWN MA 02472 |
Matthew C Kapusta | director, officer: CEO, Managing Director | 7358 MCVAY ROAD, GERMANTOWN TN 38138 |
Kuta Alexander Edward Iii | officer: Executive VP, Operations | 239 WILLIS ROAD, SUDBURY MA 01776 |
From GuruFocus
By Value_Insider Value_Insider • 12-16-2022
By PurpleRose PurpleRose • 07-13-2022
By Value_Insider Value_Insider • 12-20-2022
By PurpleRose PurpleRose • 08-08-2022
By sperokesalga sperokesalga • 05-09-2023
By sperokesalga sperokesalga • 06-21-2023
By Value_Insider Value_Insider • 11-17-2022
By Business Wire • 06-22-2023
By sperokesalga sperokesalga • 05-02-2023
By Marketwired • 10-02-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.